Investors
Information for investors including share information, share analysis, shareholder news and annual reports.
Q1 2013 results: 24 Apr 2013
View Q1 results details and CFO video
Reasons to invest in GlaxoSmithKline - a leading pharmaceutical company enabling people to do more, feel better and live longer.
Find out how GSK is performing with our Annual Report, Corporate Responsibility Report and financial summary.
Press releases
GSK receives offer for its thrombosis brands and related manufacturing site
GlaxoSmithKline (LSE: GSK) has today received an offer for its thrombosis brands and Notre-Dame de Bondeville (NDB) site from Aspen Global Incorporated and Aspen Pharmacare Holdings Limited.
GSK statement regarding 2010 Nature Medicine study
GSK and Nature Medicine recently became aware of allegations of misrepresentation of data in a research paper written by scientists at GSK’s China research centre and published in Nature Medicine in 2010.
GSK statement in response to FDA Advisory Committee’s vote on availability of Avandia (rosiglitazone)
GlaxoSmithKline [NYSE: GSK] confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to continue to make Avandia (rosiglitazone) available to appropriate patients with the majority of the members voting to either modify (13) or remove (7) the Risk Evaluation and Mitigation Strategy (REMS) program in place. Remaining members voted to continue the REMS (5) or withdraw (1) Avandia from the US market.
| GlaxoSmithKline plc |
Tel: 020 8047 5000 |
| 980 Great West Road |
Fax: 020 8047 7807 |
| Brentford |
|
| Middlesex TW8 9GS |
